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Nuclear factor erythroid-2 related factor 2 (NRF2) is a redox-sensitive transcription factor that
positively regulates the expression of genes encoding antioxidants, xenobiotic detoxification
enzymes, and drug efflux pumps, and confers cytoprotection against oxidative stress and
xenobiotics in normal cells. Kelch-like ECH-associated protein 1 (KEAP1) negatively regulates
NRF2 activity by targeting it to proteasomal degradation. Increased expression of cellular
antioxidants and xenobiotic detoxification enzymes has been implicated in resistance of tumor
cells against chemotherapeutic drugs.
Methods and Findings
Here we report a systematic analysis of the KEAP1 genomic locus in lung cancer patients and
cell lines that revealed deletion, insertion, and missense mutations in functionally important
domains of KEAP1 and a very high percentage of loss of heterozygosity at 19p13.2, suggesting
that biallelic inactivation of KEAP1 in lung cancer is a common event. Sequencing of KEAP1 in
12 cell lines and 54 non-small-cell lung cancer (NSCLC) samples revealed somatic mutations in
KEAP1 in a total of six cell lines and ten tumors at a frequency of 50% and 19%, respectively. All
the mutations were within highly conserved amino acid residues located in the Kelch or
intervening region domain of the KEAP1 protein, suggesting that these mutations would likely
abolish KEAP1 repressor activity. Evaluation of loss of heterozygosity at 19p13.2 revealed allelic
losses in 61% of the NSCLC cell lines and 41% of the tumor samples. Decreased KEAP1 activity
in cancer cells induced greater nuclear accumulation of NRF2, causing enhanced transcriptional
induction of antioxidants, xenobiotic metabolism enzymes, and drug efflux pumps.
Conclusions
This is the first study to our knowledge to demonstrate that biallelic inactivation of KEAP1 is a
frequent genetic alteration in NSCLC. Loss of KEAP1 function leading to constitutive activation
of NRF2-mediated gene expression in cancer suggests that tumor cells manipulate the NRF2
pathway for their survival against chemotherapeutic agents.
The Editors’ Summary of this article follows the references.
PLoS Medicine | www.plosmedicine.org October 2006 | Volume 3 | Issue 10 | e420 1865
PLoS MEDICINEIntroduction
Lung carcinomas are the leading cause of cancer deaths in
the United States and worldwide in both men and women.
Non-small-cell lung cancer (NSCLC) accounts for approx-
imately 85% of lung cancer cases, with 65% of these patients
presenting with unresectable stage III and IV disease [1].
Chemotherapy for advanced, inoperable NSCLC is generally
palliative. The major factor contributing to the failure of
chemotherapy in lung cancer is the development of drug
resistance [2]. Several studies have shown that the expression
of xenobiotic metabolism genes (glutathione-S-transferases
[GSTs]), antioxidants (glutathione [GSH]), and drug efﬂux
proteins (multidrug resistance protein [MRP] family) is
increased in NSCLC [3–6]. Xenobiotic metabolism enzymes
in conjunction with drug efﬂux proteins act to detoxify
cancer drugs, whereas antioxidants confer cytoprotection by
attenuating drug-induced oxidative stress and apoptosis.
Nuclear factor erythroid-2 related factor 2 (NRF2), a cap ’n’
collar basic leucine zipper transcription factor, regulates a
transcriptional program that maintains cellular redox ho-
meostasis and protects cells from oxidative insult, including
from chemotherapeutic agents [7–9]. NRF2 activates tran-
scription of its target genes through binding speciﬁcally to
the antioxidant response element (ARE) found in those gene
promoters. The NRF2-regulated transcriptional program
includes a broad spectrum of genes, including ones encoding
antioxidants (e.g., c-glutamyl cysteine synthetase modiﬁer
subunit [GCLm], c-glutamyl cysteine synthetase catalytic
subunit [GCLc], heme oxygenase-1, superoxide dismutase,
glutathione reductase [GSR], glutathione peroxidase, thiore-
doxin, thioredoxin reductase, peroxiredoxins[PRDX], and
cysteine/glutamate transporter [SLC7A11]) [7,8], xenobiotic
metabolism enzymes (e.g., NADP[H] quinone oxidoreductase
1 [NQO1], GSTs, and UDP-glucuronosyltransferase) [7,8], and
several ATP-dependent drug efﬂux pumps (e.g., MRP1 and
MRP2) [10–12].
Disruption of NRF2 in mice enhances oxidative damage
and inﬂammation in lungs on exposure to cigarette smoke [7],
diesel exhaust [13], lipopolysaccharide [14], and allergen [15].
Nrf2-deﬁcient mice have lesser expression of xenobiotic
enzymes and are greatly predisposed to tumors induced by
carcinogens such as benzo(a)pyrene and aﬂatoxin [16]. By
virtue of its central role in the transactivation of detoxiﬁca-
tion genes involved in the cellular responses to oxidative or
electrophilic stresses, NRF2 activation is being targeted for
cancer chemoprevention [17]. Recent studies have also
demonstrated that NRF2 protects against apoptosis induced
by oxidants and also by FAS ligand [7,18]. Phosphorylation of
NRF2 by protein kinase(s) associated with the MAPK/ERK
signaling cascade increases stabilization of NRF2 and has
been proposed as an important mechanism leading to
increased expression of ARE-dependent genes [11].
Kelch-like ECH-associated protein 1 (KEAP1) is a cytoplas-
mic anchor of NRF2 that also functions as a substrate adaptor
protein for a Cul3-dependent E3 ubiquitin ligase complex to
maintain steady-state levels of NRF2- and NRF2-dependent
transcription [19,20]. KEAP1 is located at 19p13.2 and has
three major domains: an N-terminal broad complex, tram-
track, and bric-a-brac (BTB) domain; a central intervening
region (IVR); and a series of six C-terminal Kelch repeats [21]
(Figure 1). The Kelch repeats of KEAP1 bind the Neh2
domain of NRF2, whereas the IVR and BTB domains are
required for the redox-sensitive regulation of NRF2 through
a series of reactive cysteines present throughout this region
[22]. KEAP1 constitutively suppresses NRF2 activity in the
absence of stress; however, oxidants, xenobiotics, and electro-
philes hamper the KEAP1-mediated proteasomal degradation
of NRF2, which results in increased nuclear accumulation
and, in turn, the transcriptional induction of target genes
that ensure cell survival. [7,23] Recently, Padmanabhan et al.
[24] reported a heterozygous somatic mutation (G430C) in
KEAP1 in one lung cancer tumor and a G364C mutation in an
adenocarcinoma and a small cell lung cancer cell line.
To investigate the NRF2–KEAP1 pathway in lung cancer we
ﬁrst examined the status of the KEAP1 locus at 19p13.2. We
also sequenced KEAP1 in 12 cell lines and 56 tumor samples
obtained from lung cancer patients. Since KEAP1 is an
inhibitor of NRF2-mediated gene expression, we monitored




Tumors for this study were randomly selected from 700
freshly frozen lung cancer tissues from patients who had
undergone complete, curative resection of their disease from
1993 to 2001 at Johns Hopkins Hospital, Baltimore, Maryland,
United States. Tumors were macrodissected and only those
specimens with greater than 50% neoplastic cells were used.
A total of 56 cases of lung tumor, including 40 paired lung
tumors and adjacent normal tissues (frozen tissue) and 16
pleural ﬂuid (PF) samples, were chosen in accordance with
the Institutional Review Board protocol, and DNA was
isolated using DNeasy Kit (Qiagen, Valencia, California,
United States). Details of the lung tumor samples are listed
in Table S1.
PCR and Sequence Analysis
The genomic sequence of human KEAP1 was downloaded
from the NCBI human genome database. Primers for PCR
ampliﬁcation and sequencing of KEAP1 were designed using
Primer3 software (http://fokker.wi.mit.edu) and synthesized by
Integrated DNA Technologies (Coralville, Iowa, United
States). PCR ampliﬁcation of DNA from early passage cell
lines or primary tumors (PTs) was carried out using ExTaq
Premix from Takara Mirus Biosciences (Madison, Wisconsin,
United States) and 10 pmol of each primer. PCR products
were directly sequenced after puriﬁcation (QIAquick PCR
puriﬁcation kit, Qiagen). Sequencing was carried out at the
DNA sequencing core facility located at Johns Hopkins
University. The sequence data were downloaded, assembled,
and analyzed to identify potential genetic alterations. All
mutations were conﬁrmed by sequencing in both directions.
PCR products from samples showing deletion mutation were
reampliﬁed using high-ﬁdelity Taq polymerase (Applied
Biosystems, Foster City, California, United States) and cloned
into TOPO TA cloning vector (Invitrogen, Carlsbad, Cal-
ifornia, United States), and ﬁve clones from each sample were
sequenced. All deletions were present in at least two of the
ﬁve clones sequenced. Exons harboring mutations were
reampliﬁed from the original DNA and sequenced. Chroma-
tograms were analyzed by manual review. Sequences of all the
PLoS Medicine | www.plosmedicine.org October 2006 | Volume 3 | Issue 10 | e420 1866
KEAP1 Mutations in Lung Cancerprimers used for ampliﬁcation are in Table S2. The PCR
cycling conditions were 94 8C (3 min) for one cycle, 94 8C (30
s), 65 8C (45 s), and 72 8C (1 min) for 35 cycles, and a ﬁnal
extension of 72 8C (5 min).
Microsatellite-Based Loss of Heterozygosity Analysis
The Cancer Genome Project at Sanger Institute (Cam-
bridge, United Kingdom) genotyped 829 cell lines with 395
polymorphic CA/GT repeat markers that provide a 10-cM
resolution map of the human genome. The markers are
sourced from the ABI Prism LD20 set (data available at http://
www.sanger.ac.uk/cgi-bin/genetics/CGP/genotyping/lohmap).
Of the 829 cell lines genotyped, 191 were lung cancer cell
lines. We obtained the raw data from Sanger Institute and
analyzed it, and the results are presented in the form of a heat
map. Fluorescent loss of heterozygosity (LOH) analysis using
genomic DNA from matched normal and lung tumor tissues
was performed using two novel microsatellite markers.
Contig AC011461.5.1.100680, containing KEAP1 ﬂanking
sequences, was downloaded from the Ensembl database
(http://www.ensembl.org/Homo_sapiens). Two pairs of ﬂuo-
rescently labeled microsatellite primers ﬂanking KEAP1
(KEAP-UM1 [CA17], present upstream of the KEAP1 locus,
and KEAP-DM1 [CA21], present downstream of the KEAP1
locus) were designed using Primer3 software and synthesized
by Integrated DNA Technologies. Brieﬂy, each PCR reaction
was performed in a total volume of 10 ll containing 50 ng
DNA, 10 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl2,
0.01% gelatin, 200 lM dNTPs, 10 pmol of each primer, and
0.1 U Ampli Taq GOLD DNA polymerase (Applied Bio-
systems). Cycling conditions were 94 8C (10 min) for one cycle,
94 8C (30 s), 66–67 8C (30 s), and 72 8C (30 s) for 25 cycles, and
a ﬁnal extension of 72 8C (20 min), in a MJ Research tetrad
PCR System (Bio-Rad, Hercules, California, United States).
Details of the primer sequences are listed in Table S2. The
data were analyzed by the ABI Genescan and Genotyper
software packages (PerkinElmer, Wellesley, Massachusetts,
United States), and allelic loss was scored. The sequence and
allele size range for KEAP-DM1 and KEAP-UM1 were
determined prior to their use in the analysis of the normal
and tumor-matched lung cancer samples. In our system, a
relative allele ratio of less than 0.6, which correlates with an
allele loss of approximately 40%, was deﬁned as LOH. The
LOH was conﬁrmed at least twice for each marker.
Heat Maps
Heat maps were constructed using GeneCluster and Tree-
view software (M. Eisen; http://rana.lbl.gov/EisenSoftware.
htm). For displaying gene expression values for the different
normal and cancer cell lines, the relative fold changes for
individual cell lines were normalized to the maximum fold
change value across all cell lines, for a particular gene.
Western Blot Analysis
To obtain total protein lysates, cancer cells or tissues were
lysed in 50 mM Tris (pH 7.2), 1% Triton X-100 containing
Halt Protease Inhibitor cocktail (Pierce, Rockford, Illinois,
United States) and centrifuged at 12,000g for 15 min at 4 8C.
To obtain nuclear extracts, NE-PER Nuclear Extraction
Reagents (Pierce) were used. Protein concentrations were
estimated by the BCA method (Pierce).
For immunoblot analysis, 30 lg and 100 lg of protein from
nuclear extracts and total protein lysates, respectively, were
used and resolved on 10% SDS-PAGE gels. Proteins were
transferred onto PVDF membranes, and the following anti-
bodies were used for immunoblotting: anti-KEAP1 (gift from
M. Velichkova, University of California San Diego, La Jolla,
California, United States), anti-NRF2 (H-300; Santa Cruz
Biotechnology, Santa Cruz, California, United States), anti–
Lamin B1 (Santa Cruz Biotechnology), and anti-GAPDH
(Imgenex, Sorrento Valley, California, United States). All
primary antibodies were diluted in PBS-T/5% nonfat dry milk
and incubated overnight at 4 8C.
Enzyme Assay
Enzyme activities of GST, GSR, and NQO1 were deter-
mined in the total protein lysates by following methods
previously described [8]. Total glutathione (oxidized and
reduced) was determined using a modiﬁed Tietze method [25]
by measuring reduction of 5,59-dithiobis-2-nitrobenzoic acid
in a GSR-coupled assay.
In Vitro Transcription/Translation
Human KEAP1 and NRF2 cDNA was in vitro transcribed
and translated using in vitro transcription/translation reac-
tions. These were performed in T7 TNT reticulocyte lysate
(Promega, Madison, Wisconsin, United States) following the
supplier’s instructions.
Immunohistochemistry
Formalin-ﬁxed tissues were treated with anti-NRF2 anti-
body (H-300, Santa Cruz Biotechnology) at a dilution of 1:250
for 1 h and developed using horseradish peroxidase (Dako,
Glostrup, Denmark). Non-immune rabbit IgG (Jackson
ImmunoResearch Laboratories, West Grove, Pennsylvania,
United States) was used as a negative control. To demonstrate
the speciﬁcity of antibody staining, we preincubated the anti-
NRF2 antibody with NRF2 and luciferase in vitro transcribed
and translated protein, respectively, for 30 min and then
carried out immunohistochemical staining.
Figure 1. Schematic of the Conserved Domain Structure of Human KEAP1 Protein
The protein consists of an N-terminal region (amino acids 1–60), a BTB domain (amino acids 61–179), a central IVR (amino acids 180–314), a double-
glycine-rich region comprising six Kelch motifs (amino acids 315–359, 361–410, 412–457, 459–504, 506–551, and 553–598), and a C-terminal domain
(amino acids 599–624). The frequency of mutations detected within each domain is indicated below. Amino acid positions of the mutations are listed in
Table 1.
DOI: 10.1371/journal.pmed.0030420.g001
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Total RNA was extracted from cells using RNeasy kit
(Qiagen) and was quantiﬁed by UV absorbance spectropho-
tometry. The reverse transcription reaction was performed
by using the Superscript First-Strand Synthesis System
(Invitrogen) in a ﬁnal volume of 20 ll containing 2 lgo f
total RNA, 100 ng of random hexamers, 13 reverse tran-
scription buffer, 2.5 mM MgCl2, 1 mM dNTP, 10 U of
RNaseOUT, 20 U of Superscript reverse transcriptase, and
DEPC-treated water. Quantitative real-time RT-PCR analyses
of human KEAP1, NRF2, GCLc, GCLm, GSR, PRDX1, GSTA3,
GSTA2, NQO1, MRP1, and MRP2 were performed by using
Assay-on-Demand primers and probe sets from Applied
Biosystems. Assays were performed by using the ABI 7000
Taqman system (Applied Biosystems). b-actin was used for
normalization.
Plasmid Construction
Plasmid encoding human KEAP1 cDNA in pCMV6-XL5 was
purchased from Origene Technologies (Rockville, Maryland,
United States). Glycine-to-serine mutations, leucine-to-argi-
nine mutations, and a single nucleotide deletion were
introduced into the KEAP1 expression vector by using a
site-directed mutagenesis kit (Stratagene, La Jolla, United
States). Details of the site-directed mutagenesis primers used
in this study are listed in Table S2.
Cell Culture and Reagents
HBE4, NL20, A549, H460, H1435, H292, H23, H358, H1299,
H1993, H1395, and H838 cells were purchased from
American Type Culture Collection (Manassas, Virginia,
United States) and cultured under recommended conditions.
BEAS2B cells were provided by S. Reddy (Johns Hopkins
University, Baltimore, Maryland, United States). All trans-
fections were carried out using Lipofectamine 2000 (Invi-
trogen).
Generation of Stable Transfectants
H838 cells overexpressing ARE luciferase reporter plasmid
were obtained by transfecting H838 cells with 3 lgo fNQO1-
ARE reporter plasmid and 0.3 lg of pUB6 empty vector
(Invitrogen). Stable transfectants were selected using Blasti-
cidin at a concentration of 6 lg/ml. Stable clones were
expanded and screened for the expression of ARE luciferase.
Luciferase Assay
H838 cells stably expressing NQO1-ARE luciferase were
seeded onto a 24-well dish at a density of 0.2310
6 cells/ml for
Figure 2. Somatic Alterations in KEAP1 in Lung Cancer
(A) LOH at the 19p13.1–13.3 region. A heat map depicts microsatellite-based LOH at 19p13.1–19p13.3 in 181 lung cancer cell lines. Tumor-derived cell
lines that were non-informative for this region were not included. Microsatellite markers showing heterozygous typings are depicted in red, markers
demonstrating homozygous typing are in green, and non-informative markers in black. Each vertical column represents one cell line. ET, endocrine
tumors; NS, no subtype specified; SCC, small cell carcinoma.
(B) Sequence analysis of KEAP1 mutations in lung cancer. Part a shows the H838 cell line showing C–A substitution (G–T, plus strand), resulting in a
termination codon. Wild-type sequence is from BEAS2B. A wild-type allele was not detected in H838. Part b shows a 18-bp deletion in one allele but not
in the other allele in the PF DNA sample from PF-8. Part c shows tumor PT-23, showing A–T substitution in one allele but not in the other allele. Part d
shows a 2-bp deletion in the fourth exon of KEAP1 that was detected in one allele of PT-17. Samples showing deletion mutations were confirmed by
subcloning and sequencing.
(C) LOH at the KEAP1 locus in human primary lung tumors. Summary of LOH patterns of 39 NSCLC tumors. Retained microsatellites are indicated in red,
markers demonstrating allelic loss in green, markers showing genomic instability in white, and non-informative markers in black. KEAP-UM1 (CA17)i s
present upstream of the KEAP1 locus, and KEAP-DM1 (CA21) is present downstream of the KEAP1 locus.
DOI: 10.1371/journal.pmed.0030420.g002
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KEAP1 Mutations in Lung Cancer12 h before transfection. WT-KEAP1 cDNA constructs along
with the mutant cDNA constructs (G333C and L413R) were
transfected into the cells along with pRL-TK plasmid
expressing Renilla luciferase as a transfection control.
Twenty-four hours after transfection, cells were lysed and
both ﬁreﬂy and Renilla luciferase activities were measured
with a Dual-Luciferase Reporter Assay System (Promega).
siRNA Duplex Screening and Transfection
The siRNA sequence targeting NRF2 corresponds to the
coding region nucleotides 1903–1921 (59-GTAAGAAGCCA-
GATGTTAA-39) in the NRF2 cDNA. The NRF2 siRNA duplex
with the following sense and antisense sequences was used: 59-
GUAAGAAGCCAGAUGUUAAdUdU-39 (sense) and 39-dU-
dUCAUUCUUCGGUCUACAATT-59 (antisense). KEAP1 siR-
NA corresponds to the coding region nucleotides 1545–1563
(59-GGGCGTGGCTGTCCTCAAT-39)i nKEAP1 transcript
variant 2. The KEAP1 siRNA duplex with the following sense
and antisense sequences was used: 59-GGGCGUGGCUGUC-
CUCAAUdUdU-39 (sense) and 39-dUdUCCCGCACCGACAG-
GAGUUA-59 (antisense). To conﬁrm the speciﬁcity of the
inhibition, the siCONTROL non-targeting siRNA 1 (NS
siRNA; 59-UAGCGACUAAACACAUCAAUU-39) with micro-
array-deﬁned signature was used as a negative control. All of
the siRNA duplexes were synthesized by Dharmacon Research
(Lafayette, Colorado, United States). Cells in the exponential
growth phase were plated at a density of 0.2 3 10
6 cells/ml,
grown for 12 h, and transfected twice at an interval of 48 h
with 50 nM siRNA duplexes using Lipofectamine 2000 and
OPTI-MEM reduced serum medium (Invitrogen) according to
the manufacturer’s recommendations. Concentrations of
siRNAs were chosen on the basis of dose–response studies
(data not shown).
MTT Cell Viability Assay
The in vitro drug sensitivity to etoposide and carboplatin
was assessed by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphen-
yl tetrazolium bromide) assay. Cells were plated at a density of
10,000 cells for BEAS2B, 5,000 cells for A549, H460, and
H838, and 20,000 cells for H1435 in 96-well plates. They were
allowed to recover for 12 h and then exposed to various
concentrations of etoposide and carboplatin for 72 h. After
72 h, drug cytotoxicity was evaluated by using a MTT
reduction conversion assay (Sigma, Saint Louis, Missouri,
United States). Forty microliters of MTT at 5 mg/ml
concentration was added to each well, and incubation was
continued for 4 h. The formazan crystals resulting from
mitochondrial enzymatic activity on MTT substrate were
solubilized with 200 ll of dimethyl sulfoxide, and absorbance
was measured at 570 nm by using a SpectraMAX microplate
reader (Molecular Devices, Sunnyvale, California, United
States). Each combination of cell line and drug concentration
was set up in eight replicate wells, and the experiment was
repeated three times. Cell survival was expressed as absorb-
ance relative to that of untreated controls. Results are
presented as means 6 standard deviation (SD).
Results
Somatic Alterations in KEAP1 in Lung Cancer Cell Lines
Evaluation of LOH at 19p13.2 in 191 lung cancer cell lines
from the Cancer Genome Project database at the Sanger
Institute revealed allelic loss in 44% (80/181; ten lines were
non-informative) of the cell lines. Of the 72 NSCLC cell lines
analyzed in this study, 61% (44/72) showed homozygous
typing for at least two consecutive microsatellite markers at
19p13.2 (Figure 2A). To determine whether mutations in
KEAP1 were present in NSCLC, we ﬁrst ampliﬁed and
sequenced all ﬁve protein-coding exons and intron–exon
boundaries of the KEAP1 gene in a set of 12 lung cancer cell
lines. Sequencing of KEAP1 in these cell lines revealed
homozygous mutations in A549, H460, H838, and H1435,
whereas H1395 and H1993 were heterozygous for mutant
allele (Table 1). We identiﬁed ﬁve different mutations, among
which four were non-conservative amino acid substitutions. A
nonsense mutation involving G–T transversion in the fourth
exon was detected in the H838 cell line. Representative
electropherograms of the mutations are shown in Figures 2B
and S1. The microsatellite database at the Sanger Institute
showed that the H460, A549, and H838 cell lines had allelic
loss (LOH) at 19p13.2. H1435 was not included in the Sanger
Institute database. We also sequenced KEAP1 in four non-
Table 1. KEAP1 Sequence Alterations in Lung-Tumor-Derived Cell Lines and Patients
Cell Line/Patient Nucleotide Mutation Amino Acid Change Amino Acid Position Domain
H460 G–C D–H 236 IVR
A549 G–T G–C 333 First Kelch domain
H1435 G–T L–R 413 Third kelch domain
H838 G–T Frameshift (stop codon) 443 Third kelch domain
H1395 G–A G–S 350 First kelch domain
H1993 G–A G–S 350 First kelch domain
PT-23,35 A–T Q–L 284 IVR
PT-29 G–T V–F 167 BTB
PT-17 2-bp deletion (GG) Frameshift (stop codon) 413 Third kelch domain
PT-18 1-bp deletion (G) Frameshift (stop codon) 237 IVR
PT-31 1-bp deletion (G) Frameshift (stop codon) 457 Third kelch domain
PF-3 G–A I–V 264 IVR
PF-4 G-insertion Frameshift (stop codon) 348 First kelch domain
PF-8,9 18-bp deletion 6-aa deletion 555–560 Sixth kelch domain
H460, A549, H1435, and H838 had only the mutant allele. H1395 and H1993 were heterozygous for mutation. H23, H358, H1299, H1703, H292, and H1666 had no mutations.
DOI: 10.1371/journal.pmed.0030420.t001
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KEAP1 Mutations in Lung Cancermalignant (normal) human lung epithelial cell lines (BEAS2B,
NL20, HBE4, and NHBE) and found only the wild-type
sequence (Table S3).
Somatic AlterationsinKEAP1inLung Cancer Tumor Tissues
To determine whether mutations in KEAP1 are present in
lung cancer tumors, we ampliﬁed and sequenced KEAP1 in 40
primary lung tumors (25 of which were paired with normal
tissue samples) and 16 PF samples from lung cancer patients
at Johns Hopkins Hospital. The PTs included 19 adenocarci-
noma, six large cell carcinoma, and 15 squamous cell
carcinoma samples (Table S1). The PF samples included 14
non-small-cell adenocarcinoma and two small cell carcinoma
samples (Table S1). Out of 40 PTs sequenced, three tumors
(PT-23, PT-29, and PT-35) showed non-conservative amino
acid substitution in the IVR and BTB domains of KEAP1
(Table 1). PT-23 (an adenocarcinoma) and PT-35 (a large cell
carcinoma) had identical mutations resulting in Q–L amino
acid substitution in the IVR domain (Figure 2B). In addition
to this, three PTs (PT-17, PT-18, and PT-31) showed deletion
mutation in the IVR and Kelch domains, resulting in
frameshift and premature termination codons. Of the 16 PF
samples, two samples (PF-8 and PF-9) showed identical 18-bp
deletions leading to loss of six amino acids in the sixth Kelch
domain. PF-4 had a G-insertion in the third exon resulting in
frameshift mutation and truncated KEAP1 protein. I–V
substitution was detected in sample PF-3.
To ascertain the status of the KEAP1 locus in primary lung
tumors, we designed two microsatellite markers, KEAP-UM1
and KEAP-DM1, that closely ﬂank the KEAP1 gene (within
;300 kb on either side). We genotyped the PTs and their
corresponding normal DNA samples using these two markers.
PF DNA samples were not used for the LOH studies because
the corresponding normal DNA was not available. Of the 39
pairs of lung tumors genotyped, 16 tumors (41%) demon-
strated LOH for at least one of the markers (Figure 2C). Six
tumors showed only microsatellite instability in this region.
Five out of six tumors harboring KEAP1 mutation also
demonstrated LOH at these loci. In summary, out of 56
samples sequenced, 54 were NSCLC tumor samples and ten
(10/54) of these harbored mutations in KEAP1. Interestingly,
nine of the ten mutations were identiﬁed in adenocarcino-
mas. Representative electropherograms of the mutations and
LOH are shown in Figures S1 and S2.
Biological Effect of KEAP1 Mutation in Lung Cancer
To study the localization of NRF2 in primary lung tumors,
we performed immunohistochemistry on primary lung tumor
tissues using anti-NRF2 antibody. Prominent NRF2 staining
was detected in both the nucleus and cytoplasm of tumor
tissue. All four PT tissues harboring KEAP1 mutations showed
increased NRF2 staining in the nucleus and cytoplasm (Figure
3A, part a). Three tumor tissues (3/5) with wild-type KEAP1
also demonstrated increased NRF2 staining, whereas the
normal bronchus from the same individuals showed very
weak staining (Figure 3A, parts c and d). Two tumor tissues
with wild-type KEAP1 showed very weak staining (Figure 3A,
part b). We also did immunohistochemistry on ﬁve normal
bronchi and did not ﬁnd any signiﬁcant staining. To conﬁrm
the speciﬁcity of anti-NRF2 antibody staining, we used in
vitro transcribed/translated NRF2 and luciferase (negative
control) protein. Incubation of anti-NRF2 antibody with
NRF2 protein dramatically reduced the staining, whereas
incubation with luciferase protein had no effect on NRF2
antibody staining (Figure S3).
We also studied levels of known NRF2 targets in tumor
samples by measuring NQO1 and GST enzyme activities and
total GSH levels in 13 pairs of primary NSCLC tumors and
adjacent normal tissues. Among these, four pairs (4/13) of
samples were from individuals harboring KEAP1 mutation.
Both NQO1 and total GST activities and GSH levels were
signiﬁcantly higher in tumor tissues than in their corre-
sponding normal bronchi (Figure 3B).
To determine whether KEAP1 mutations correlated with
NRF2 activation, we performed immunoblot analysis to
examine the nuclear accumulation of NRF2. For this study,
we selected four NSCLC cell lines—H460, A549, H1435, and
H838—all harboring KEAP1 mutations, and three non-
malignant (normal) cell lines—BEAS2B, NL20, and HBE4.
Cancer cells demonstrated increased nuclear localization of
NRF2 in comparison with normal cells (Figures 4A–4C and
Figure 3. Dysfunctional KEAP1–NRF2 Interaction in NSCLC Tumors
(A) Immunohistochemical analysis of NRF2 in NSCLC tissues. Part a shows
a patient (PT-18) with mutation in KEAP1 showing strong nuclear and
cytoplasmic staining. Part b shows a patient negative for mutation (PT-
28) showing weak cytoplasmic staining. Part c shows a patient negative
for mutation (PT-20) showing increased nuclear and cytoplasmic staining
in tumor tissue. Part d shows weakly staining normal bronchus from the
same patient (PT-20).
(B) Total GSH and enzyme activities of NQO1 and total GST in NSCLC and
matched normal tissues. Raw data for the heat maps are presented in
Table S4. *, samples harboring KEAP1 mutation; §, nmol/mg protein;
,
nmol DCPIP reduced/min/mg protein; z, nmol of product formed/min/
mg protein.
DOI: 10.1371/journal.pmed.0030420.g003
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KEAP1 Mutations in Lung CancerS4). Total NRF2 level was also higher in cancer cells,
suggesting that there was increased stabilization of NRF2 in
the absence of functional KEAP1. Real-time RT-PCR analysis
of NRF2 and NRF2-dependent target genes revealed that the
majority of the NRF2 target genes were upregulated in the
cancer cells (Figure 4D). Expression of MRP2, known to
confer drug resistance, was 100- to 1,000-fold higher in
cancer cells. Transcript levels of NRF2 did not vary consid-
erably between the two groups. As expected, NQO1 and GSR
activities and total GSH levels were signiﬁcantly higher in
cancer cells (Figure 5). We also analyzed the relative levels of
KEAP1 transcript and protein in cancer cells and normal
cells. Importantly, expression of KEAP1 mRNA was down-
regulated in three cancer cell lines—A549, H1435, and H838
(Figure 4D)—and KEAP1 protein was downregulated in all
four cancer cell lines in comparison with expression in non-
malignant cells (Figures 4A–4C and S4).
Somatic Mutations Reduce KEAP1-Mediated Repression of
NRF2
To determine the functional consequences of tumor-
derived mutations on KEAP1 activity and resultant increases
in NRF2 activity, we generated cDNAs harboring the same
mutations seen in tumor cell lines, A549 (G333C) and H1435
(L413R). We also generated a mutant KEAP1 construct
harboring a single base pair deletion seen in PT-18. We
transfected the wild-type and mutant constructs of KEAP1
into H838 cells stably expressing an ARE reporter. Impor-
tantly, all of the three mutants of KEAP1 could not repress
the activity of NRF2, whereas overexpression of WT-KEAP1
completely abolished the NRF2-mediated ARE reporter
activity (Figure 6A). To further demonstrate that NRF2
activation contributes to the increased expression of anti-
oxidants, xenobiotic metabolism enzymes, and drug efﬂux
pumps in cancer cells, we challenged A549 cells with siRNA
targeting NRF2, and BEAS2B cells with KEAP1 siRNA. We
Figure 4. Status of KEAP1 and NRF2 Is Altered in Cancer Cells
(A) Immunoblot showing increased nuclear localization of NRF2 in nuclear extracts (NE) from cancer cells. Cancer cells showed lower levels of KEAP1
(;69 kDa) and higher levels of NRF2 (;110 kDa) in total protein lysates (TP). NIVT and KIVT indicate NRF2 and KEAP1 in vitro transcribed/translated
product, respectively.
(B and C) Quantification of NRF2 and KEAP1 protein in immunoblots. For band densitometry, bands in nuclear extract blot (B) were normalized to Lamin
B1, and those in total protein (C) were normalized to GAPDH.
(D) Heat map showing relative expression of KEAP1, NRF2, and NRF2-dependent genes by real-time RT-PCR. Raw data for the heat maps are presented in
Table S5.
DOI: 10.1371/journal.pmed.0030420.g004
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KEAP1 Mutations in Lung Cancermeasured the transcript levels of NRF2, NQO1, GSR, GCLc,
GCLm, MRP1, and MRP2 by real-time RT-PCR. A non-
targeting siRNA (NS siRNA) with microarray-deﬁned signa-
ture was used as control. Transfection of NRF2 siRNA in
cancer cells decreased the NRF2 message by 80% and
simultaneously downregulated the expression of NRF2 target
genes (Figure 6B). Conversely, inhibition of KEAP1 expres-
sion by siRNA induced the expression of NRF2-driven genes
in BEAS2B cells (Figure 6C).
Constitutive Activation of NRF2 Confers Chemoresistance
To elucidate a possible role for NRF2 in conferring
chemoresistance, we analyzed the drug resistance proﬁle of
normal lung epithelial cells and cancer cells harboring KEAP1
mutation. Cells were exposed to various concentrations of
etoposide and carboplatin, and cell viability was measured
after 72 h. As shown in Figure 7, BEAS2B cells with wild-type
KEAP1 demonstrated enhanced sensitivity to both the drugs
when compared with that of cancer cells. Reduced chemo-
sensitivity of cancer cells with high NRF2 activity suggests
that NRF2 contributes to drug resistance by regulating the
expression of several plasma membrane efﬂux pumps, such as
MRP1 and MRP2, and phase II detoxiﬁcation enzymes.
Discussion
NRF2, a bZIP transcription factor, activates cellular rescue
pathways against oxidative injury, inﬂammation, apoptosis,
and carcinogenesis through transcriptional induction of a
broad spectrum of genes involved in xenobiotic detoxiﬁca-
tion and antioxidant protection [7,8,15]. KEAP1 anchors the
NRF2 transcription factor within the cytoplasm, targeting it
for ubiquitination and proteasomal degradation, thus re-
pressing its ability to induce cytoprotective genes. LOH at the
short arm of Chromosome 19 (19p13.2), where KEAP1 is
located, has been reported in lung cancer [26,27], breast
carcinoma [28], prostate cancer [29], oral cancer [30], and gall
bladder carcinoma. A genome-wide search for LOH in lung
cancer cell lines identiﬁed Chromosome 19p as a candidate
tumor suppressor region showing more than 60% LOH [26].
Evaluation of LOH at 19p13.2 in lung cancer cell lines from
the Cancer Genome Project database at the Sanger Institute
revealed allelic losses in 61% of the NSCLC cell lines. We
detected point mutations leading to non-conservative amino
acid substitutions and nonsense mutations in 50% (6/12) of
the cell lines sequenced (Table 1), and all the mutations
altered highly conserved amino acid residues located in the
Kelch or IVR domain of the KEAP1 protein, suggesting that
these mutations would likely abolish KEAP1 repressor
activity. Three cell lines—A549, H838, and H1435—displayed
G–T transversions, the type of DNA damage expected from
bulky DNA adducts caused by the polycyclic hydrocarbons
and nitrosoamines in tobacco smoke [31]. Only the mutant
allele, and not the wild-type, was detected in the H460, A549,
H1435, and H838 cell lines, which suggests that the mutations
were either homozygous (which is unlikely) or hemizygous
(with corresponding LOH affecting the other allele). The
microsatellite database at the Sanger Institute revealed that
H460, A549, and H838 cell lines had allelic loss at 19p13.2,
which conﬁrms that the wild-type KEAP1 allele was lost by
LOH and that the retained allele was inactivated by somatic
mutations. H1435 was not included in the Sanger Institute
database.
Sequencing of KEAP1 in 40 primary lung tumors and 16 PF
samples from lung cancer patients revealed deletion, inser-
tion, missense, and frameshift mutations in KEAP1 in a total
of ten tumors, and the frequency of mutations in PTs and PF
was 15% (6/40) and 25% (4/16), respectively. Most of the
mutations affected highly conserved amino acids located in
functionally important domains of KEAP1. We found four
different deletions and one single base pair insertion, and all
Figure 5. Comparison of Total GSH Levels, GST, NQO1, and GSR Enzyme Activities between Cancer Cells and Normal Cells
Shown are total GSH levels (A) and enzyme activities for GST (B), NQO1 (C), and GSR (D). Data represent mean 6 SD (n¼3). *, p¼0.0016; **, p¼0.039;
***, p ¼ 0.011 relative to normal cells (by t-test).
DOI: 10.1371/journal.pmed.0030420.g005
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KEAP1 Mutations in Lung Cancerof these alterations (except the 18-bp deletion) introduced a
premature stop codon that resulted in a truncated KEAP1
protein. All sequence alterations in this group were hetero-
zygous in tumor DNA and found only in the smokers.
Interestingly, the majority (9/10) of these mutations were
detected only in adenocarcinomas. No mutations were
detected in the paired normal tissue, which conﬁrms that
the tumor-derived mutations were somatic in origin. An
overall mutation frequency of 19% (10/54) for the KEAP1
gene in NSCLC tissues suggests that KEAP1 mutation is a
frequent genetic alteration in NSCLC. Microsatellite-based
genotyping of PT and paired normal tissues (39 pairs)
demonstrated LOH for at least one of the markers in 41.0%
(16/39) of the PTs. Five of the six PTs harboring KEAP1
mutations showed LOH of KEAP1; thus, as deﬁned by the
Knudson two-hit model, there was biallelic inactivation of
KEAP1 in these tumors [32]. In addition, given the intrinsic
difﬁculties of genetic analysis in PTs, which are invariably
contaminated with normal cells, we expect this frequency of
mutation and LOH to be an underestimate. Detection of
KEAP1 alterations in early stages of lung tumor development
(stage IB, Table S1) further suggests that loss of KEAP1
function may be an early event in lung cancer pathogenesis.
Future studies aimed at systematic evaluation of KEAP1
status in preinvasive preneoplastic lesions such as hyper-
plasia, dysplasia, and carcinoma in situ, as well as in late-stage
invasive carcinoma, will provide insights regarding the role of
the KEAP1–NRF2 pathway in tumor progression.
Keap1-null mutation in mice results in postnatal lethality
because of constitutive Nrf2 activation, whereas heterozygous
mutation of Keap1 has no effect on Nrf2 activity [23]. This
ﬁnding suggests that loss of both functional KEAP1 alleles is
essential for constitutive activation of NRF2-mediated gene
expression. Thus, a heterozygous mutation in KEAP1, as
reported recently [24], may not effect NRF2-mediated
cytoprotective gene expression. Here, we report—to our
knowledge for the ﬁrst time—biallelic inactivation of KEAP1
in NSCLC, which we believe would result in constitutive
activation of NRF2.
In corroboration with the above ﬁndings that suggest loss
of functional KEAP1 in lung cancers, immunohistochemical
staining of NRF2 in lung adenocarcinoma tissues showed
increased staining in tumor tissue compared to paired
normal tissue. As anticipated, NQO1 and GST enzyme
activities and GSH levels were signiﬁcantly elevated in the
tumors compared with those in the matched normal tissue. In
the absence of functional KEAP1 activity, cancer cells
demonstrated an increased nuclear accumulation of NRF2
as well as an increase in total NRF2. Predictably, the NQO1
and GSR enzyme activities and GSH levels were signiﬁcantly
higher in cancer cells. Expression analysis of NRF2-depend-
ent genes revealed upregulation of antioxidant genes,
detoxiﬁcation enzymes, and drug efﬂux pumps in the cancer
cells. GSH and related detoxiﬁcation enzymes, including
GSH-conjugating efﬂux pumps, are involved in the detox-
iﬁcation of anti-neoplastic drugs and by-products of oxida-
tive stress. Upregulation of GSH and related enzymes in
tumor tissues probably contributes to the observed high
resistance to cytotoxic drugs and cell death [5].
The high antioxidant capacity of NSCLC cells increases cell
survival and proliferation and protects against oxidants,
radiation, and chemotherapies, thus conferring the chemo-
Figure 6. Mutant KEAP1 Protein Is Unable to Suppress NRF2 Activity
(A) Repression activity of the KEAP1 mutants was monitored by a
luciferase reporter assay. Wild-type and mutant KEAP1 cDNA constructs
were transfected onto H838 cells stably expressing ARE luciferase
reporter. Data represent mean 6 SD (n ¼ 3).
(B) Silencing of NRF2 by siRNA in A549 cells downregulated the
expression of NRF2-dependent genes. A nonspecific siRNA (NS siRNA)
was used as control.
(C) Inhibition of KEAP1 expression by siRNA in BEAS2B cells upregulated
the expression of NRF2-dependent genes.
DOI: 10.1371/journal.pmed.0030420.g006
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KEAP1 Mutations in Lung Cancerresistance phenotype [3,5]. Levels of GSH-conjugating
enzymes have been shown to be higher in cell lines derived
from NSCLC cells than in small cell lung cancer cell lines [33].
Others have speculated that these alterations may account for
the differences in drug sensitivity between these tumor types
[6]. Several studies have documented that GSH concentra-
tions are high in drug-resistant cancer cell lines and that cell
viability can be modulated with buthionine sulfoximine,
which causes GSH depletion [34,35].
Expression of the wild-type KEAP1 in H838 cells stably
expressing an ARE reporter completely abolished ARE
reporter activity, whereas overexpression of the KEAP1
mutant construct did not, suggesting that the somatic
mutations hamper the association between KEAP1 and
NRF2 and consequently activate NRF2. Critically, the
enhanced expression of various antioxidants and detoxiﬁca-
tion genes was veriﬁed to be NRF2-dependent, because siRNA
targeted against NRF2 transcript attenuated the expression of
these NRF2-dependent genes in A549 cells. However, our
understanding of NRF2-regulated genes is based on genomic
proﬁling of Nrf2 wild-type and knock out mice in response to
different environmental stress [7,8,15]. Other than the
cellular antioxidants and xenobiotic enzymes, the global
transcriptional program regulated by constitutive activation
of NRF2 in tumor cells remains unknown. Elucidation of
NRF2-dependent pathways in tumor cells will provide a
better understanding of this novel chemoresistance factor.
Increased NRF2 staining and NRF2-dependent enzyme
activities in tumor samples with wild-type KEAP1 suggests
that there are other possible mechanisms operating in tumor
cells that contribute to increased stabilization and activation
of NRF2 [11,36]. For example, Prothymosin a, an extremely
abundant nuclear oncoprotein, has been recently demon-
strated to be an intranuclear dissociator of NRF2–KEAP1
complex and to upregulate expression of NRF2 target genes
[36,37]. Another possible mechanism is differential splicing of
KEAP1, leading to nonfunctional KEAP1 protein product in
cancer cells. Alternatively spliced KEAP1 transcript lacking
exon 5 is reported in human large cell lung carcinoma (NCBI
human genome database). Also, KEAP1 downregulation by
promoter methylation cannot be ruled out because the
KEAP1 promoter contains CpG-rich regions. It is also
possible that chronic oxidative stress, resulting from in-
creased metabolic activity in cancer cells, is contributing to
activation of NRF2. Thus, more intensive studies are needed
to unravel the mechanisms responsible for exaggerated NRF2
response in cancer cells even in the presence of wild-type
KEAP1.
In summary, though activation of the NRF2 pathway in
normal cells confers cytoprotection against oxidative stress
and carcinogens, unrestrained activation of the same tran-
scriptional program in cancer cells may provide selective
growth advantages to tumors over normal somatic cells. The
identiﬁcation of KEAP1 mutations in a subset of NSCLC
samples and the association between loss of functional
KEAP1 and increased NRF2 activity extends the emerging
paradigm whereby increased expression of antioxidants,
detoxiﬁcation enzymes, and drug transporters favors malig-
nant progression and renders tumors resistant to chemo-
therapy. While the number of tumors examined in this study
is not sufﬁciently large to lead to a deﬁnitive conclusion, this
study is the ﬁrst to our knowledge to show that mutations and
LOH in KEAP1, as well as possibly other non-mutation-based
mechanisms, enable high NRF2 activity in primary lung
tumors. It remains to be determined whether such a
mechanism operates in cancers arising in other organs such
as ovary, pancreas, brain, and breast, where chemoresistance
is a major issue, and whether high NRF2 activity in tumors
can be a biomarker of poor prognosis. If future experiments
verify that enhanced activation of NRF2 is a key cause of
chemoresistance and poor prognosis, one could envision
development of speciﬁc siRNA or small molecule inhibitors
of NRF2 for treatment of patients with tumors resistant to
chemotherapy.
Figure 7. Increased NRF2 Activity Confers Chemoresistance
BEAS2B cells and cancer cells were exposed to etoposide (A) or
carboplatin (B) for 72 h, and viable cells were determined by MTT assay.
BEAS2B cells displayed enhanced sensitivity whereas cancer cells with
dysfunctional KEAP1 activity demonstrated reduced chemosensitivity to
etoposide and carboplatin treatment. Data are presented as percentage
of viable cells relative to the vehicle-treated control. Data are the mean
of eight independent replicates, combined to generate the mean 6 SD
for each concentration.
DOI: 10.1371/journal.pmed.0030420.g007
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Figure S1. Sequence Analysis Reveals Mutations in KEAP1 in Lung
Cancer Cell Lines and Tumor Tissues
(A) Representative DNA sequence data from lung cancer cell lines.
The wild-type sequences are from the non-malignant cell line
BEAS2B. Only the mutant allele was detected in the cancer cell lines
shown.
(B) Representative electropherograms depicting some of the KEAP1
mutations identiﬁed in NSCLC tumors. All the mutations identiﬁed
in patients were heterozygous.
Found at DOI: 10.1371/journal.pmed.0030420.sg001 (122 KB PDF).
Figure S2. LOH at the KEAP1 Locus in Human Primary Lung Tumors
Representative electropherograms showing partial and complete loss
of one allele and microsatellite instability at 19p13.2.
Found at DOI: 10.1371/journal.pmed.0030420.sg002 (111 KB PPT).
Figure S3. Immunohistochemical Staining of NRF2 in NSCLC Tumor
Tissue
To demonstrate the speciﬁcity of anti-NRF2 antibody staining, we
preincubated the anti-NRF2 antibody with luciferase (A) and NRF2
(B) in vitro transcribed and translated protein. Incubation of anti-
NRF2 antibody with NRF2 protein signiﬁcantly reduced the NRF2
staining.
Found at DOI: 10.1371/journal.pmed.0030420.sg003 (5.8 MB PPT).
Figure S4. Western Blot Showing Increased Nuclear NRF2 in Lung
Cancer Cells(A) Second set of immunoblot showing increased nuclear
localization of NRF2 in nuclear extracts (NE) from cancer cells.
(B and C) Quantiﬁcation of NRF2 and KEAP1 protein in immuno-
blots. For band densitometry, bands in nuclear extract blot (B) were
normalized to Lamin B1 and those in total protein (C) were
normalized to GAPDH.
Found at DOI: 10.1371/journal.pmed.0030420.sg004 (581 KB PPT).
Table S1. Pathological and KEAP1 Mutation Details of PTs and PF
Samples
Found at DOI: 10.1371/journal.pmed.0030420.st001 (70 KB PPT).
Table S2. Primer Sequences Used in Study
Found at DOI: 10.1371/journal.pmed.0030420.st002 (21 KB XLS).
Table S3. Details of Somatic Alterations in KEAP1 in Normal and
Tumor-Derived Lung Cell Lines
Found at DOI: 10.1371/journal.pmed.0030420.st003 (22 KB XLS).
Table S4. Total GSH and Enzyme Activities of NQO1 and GST in
Matched NSCLC and Normal Tissues
Found at DOI: 10.1371/journal.pmed.0030420.st004 (22 KB XLS).
Table S5. Real-Time Expression Analyses of KEAP1, NRF2, and NRF2-
Dependent Genes by Real-Time RT-PCR
Found at DOI: 10.1371/journal.pmed.0030420.st005 (18 KB XLS).
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Editors’ Summary
Background. Lung cancer is the most common cause of cancer-related
death worldwide. More than 150,000 people in the US alone die every
year from this disease, which can be split into two basic types—small cell
lung cancer and non-small-cell lung cancer (NSCLC). Four out of five lung
cancers are NSCLCs, but both types are mainly caused by smoking.
Exposure to chemicals in smoke produces changes (or mutations) in the
genetic material of the cells lining the lungs that cause the cells to grow
uncontrollably and to move around the body. In more than half the
people who develop NSCLC, the cancer has spread out of the lungs
before it is diagnosed, and therefore can’t be removed surgically. Stage
IV NSCLC, as this is known, is usually treated with chemotherapy—toxic
chemicals that kill the fast-growing cancer cells. However, only 2% of
people with stage IV NSCLC are still alive two years after their diagnosis,
mainly because their cancer cells become resistant to chemotherapy.
They do this by making proteins that destroy cancer drugs (detox-
ification enzymes) or that pump them out of cells (efflux pumps) and by
making antioxidants, chemicals that protect cells against the oxidative
damage caused by many chemotherapy agents.
Why Was This Study Done? To improve the outlook for patients with
lung cancer, researchers need to discover exactly how cancer cells
become resistant to chemotherapy drugs. Detoxification enzymes, efflux
pumps, and antioxidants normally protect cells from environmental
toxins and from oxidants produced by the chemical processes of life.
Their production is regulated by nuclear factor erythroid-2 related factor
2 (NRF2). The activity of this transcription factor (a protein that controls
the expression of other proteins) is controlled by the protein Kelch-like
ECH-associated protein 1 (KEAP1). KEAP1 holds NRF2 in the cytoplasm of
the cell (the cytoplasm surrounds the cell’s nucleus, where the genetic
material is stored) when no oxidants are present and targets it for
destruction. When oxidants are present, KEAP1 no longer interacts with
NRF2, which moves into the nucleus and induces the expression of the
proteins that protect the cell against oxidants and toxins. In this study,
the researchers investigated whether changes in KEAP1 might underlie
the drug resistance seen in lung cancer.
What Did the Researchers Do and Find? The researchers looked
carefully at the gene encoding KEAP1 in tissue taken from lung tumors
and in several lung cancer cell lines—tumor cells that have been grown
in a laboratory. They found mutations in parts of KEAP1 known to be
important for its function in half the cell lines and a fifth of the tumor
samples. They also found that about half of the samples had lost part of
one copy of the KEAP1 gene—cells usually have two copies of each gene.
Five of the six tumors with KEAP1 mutations had also lost one copy of
KEAP1—geneticists call this biallelic inactivation. This means that these
tumors should have no functional KEAP1. When the researchers checked
this by staining the tumors for NRF2, they found that the tumor cells had
more NRF2 than normal cells and that it accumulated in the nucleus. In
addition, the tumor cells made more detoxification enzymes, efflux
proteins, and antioxidants than normal cells. Finally, the researchers
showed that lung cancer cells with KEAP1 mutations were more resistant
to chemotherapy drugs than normal lung cells were.
What Do These Findings Mean? These results indicate that biallelic
inactivation of KEAP1 is a frequent genetic alteration in NSCLC and
suggest that the loss of KEAP1 activity is one way that lung tumors can
increase their NRF2 activity and develop resistance to chemotherapeutic
drugs. More lung cancer samples need to be examined to confirm this
result, and similar studies need to be done in other cancers to see
whether loss of KEAP1 activity is a common mechanism by which tumors
become resistant to chemotherapy. If such studies confirm that high
NRF2 activity (either through mutation or by some other route) is often
associated with a poor tumor response to chemotherapy, then the
development of NRF2 inhibitors might help to improve treatment
outcomes in patients with chemotherapy-resistant tumors.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030420.
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